Yoshiyuki Kakehi - Concepedia

Author

Yoshiyuki Kakehi

Also Known As

Hiroshi Sasaki, Kakehi, Yoshiyuki, Mikio Sugimoto, Shin Egawa, Tom Pickles, Y Kakehi, Y. KAKEHI, Y. Kakehi, YOSHIYUKI KAKEHI, Yoshiyuki KAKEHI

376

Publications

9.8K

Citations

H-Index

144

Concepts

All Affiliations

Kagawa University Kyoto University Tohoku University Akita University Harasanshin Hospital

About

Yoshiyuki Kakehi is an author at Kagawa University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	67	4.7K
2	Public Health	9	9	1.3K
3	Natural Sciences	6	6	453
4	Engineering	1	1	27
5	Health Sciences	1	1	31

Yoshiyuki Kakehi

161

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study Meelan Bul, Xiaoye Zhu, R. Valdagni, European Urology UrologyCancer EpidemiologyCancer ScreeningMedicineEpidemiology Of Cancer	2012	534
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial Matthew R. Smith, Chris Parker, Fred Saad, The Lancet Oncology Era 223UrologyMedicineClinical TrialsPharmacotherapy	2019	383
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment Leonard P. Bokhorst, R. Valdagni, Antti Rannikko, European Urology Epidemiological TrendPrias StudyPreventive MedicineHealth PolicyPatient Safety	2016	381
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Hiroya Oka, Yuji Chatani, Rika Hoshino, PubMed Renal PathologyMapk CascadeCancer BiologyTumor BiologySignaling Pathway	1995	301
Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Hiroshi Maéda, Seiji Hori, Hideki Nishitoh, PubMed ApoptosisCell DeathCancer BiologyTumor BiologyOncology	2001	197
Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine Hatsuo Maeda, Seiji Hori, Hiroshi Ohizumi, Cell Death and Differentiation Surgical OncologyOncologyMedicineAdvanced Solid TumorsEffective Treatment	2004	180
P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance Noriyuki Kioka, Jun Tsubota, Yoshiyuki Kakehi, Biochemical and Biophysical Research Communications GlycoproteomicsAdrenal GlandBiochemistryG Protein-coupled ReceptorNatural Sciences	1989	176
Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Tomonori Habuchi, Toshio Suzuki, Ryuichiro Sasaki, PubMed Cyp17 GeneUrologyCytochrome P450c17alpha EnzymeCancer RiskGenitourinary Cancer	2000	158
Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition) Yoshiyuki Kakehi, Mikio Sugimoto, Rikiya Taoka International Journal of Urology	2017	151
Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers Leonard P. Bokhorst, Arnout R. Alberts, Antti Rannikko, European Urology UrologyPreventive MedicineHealth PolicyCancer ScreeningMedicine	2015	150

Page 1